- Eli Lilly press release (LLY): Q3 Non-GAAP EPS of $7.02 beats by $1.13.
- Revenue of $17.6B (+53.8% Y/Y) beats by $1.53B.
- FY25 revenue consensus of $61.63B, EPS consensus of $22.50
The following table summarizes the company’s updated 2025 financial guidance:
| |
|
|
Prior
|
Updated(1) (2) (3)
|
| |
|
|
|
|
|
Revenue
|
|
|
$60.0 to $62.0 billion
|
$63.0 to $63.5 billion
|
| |
|
|
|
|
|
Performance Margin(4)
|
|
|
|
|
|
(reported)
|
|
|
42.0% to 43.5%
|
43.5% to 44.5%
|
|
(non-GAAP)
|
|
|
43.0% to 44.5%
|
45.0% to 46.0%
|
| |
|
|
|
|
|
Other Income/(Expense) (reported)
|
|
|
($750) to ($650) million
|
($700) to ($600) million
|
|
Other Income/(Expense) (non-GAAP)
|
|
|
($700) to ($600) million
|
Unchanged
|
| |
|
|
|
|
|
Tax Rate (reported)
|
|
|
Approx. 19%
|
Unchanged
|
|
Tax Rate (non-GAAP)
|
|
|
Approx. 17%
|
Unchanged
|
| |
|
|
|
|
|
Earnings per Share (reported)
|
|
|
$20.85 to $22.10
|
$21.80 to $22.50
|
|
Earnings per Share (non-GAAP)
|
|
|
$21.75 to $23.00
|
$23.00 to $23.70
|
